Released May 12, 2023, after the close
10-Q filed May 15, 2023, 45 days after period end · 0000950170-23-021976
Q1 2023 · 10-Q
Revenue$12.67M$12.67M +114.9% vs Q1 2022+46.8% vs Q4 2022
Net Income-$50.05M-$50.05M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.85-$0.85 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$42,237,000N/M
Operating Cash Flow-$60,991,000N/M
Margins · derived
Operating margin-333.3%+330.3 pt vs Q1 2022
Net margin-394.9%+268.3 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $12.67M | $5.90M | $14.66M | $7.15M |
| Net Income | -$50.05M | -$39.11M | -$30.36M | -$19.60M |
| EPS Diluted | -$0.85 | -$0.84 | -$0.66 | -$0.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR